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Résumé
Le sexe masculin et le diamètre tumoral sont des 
facteurs de risque indépendants pour une maladie 
persistante dans le cancer thyroïdien différencié
Contexte Le cancer différencié de la thyroïde (CDT) 
est l’un des néoplasmes les plus rencontrés à ce jour. 
La récurrence du CDT a été préalablement déclarée 
comme dépendante des caractéristiques de la tumeur, 
de la taille de la tumeur, de l’existence d’une métastase 
ganglionnaire, de la présence d’une invasion extra thy‑
roïdienne, de la présence de métastases à distance, des 
oncogènes comme des proto‑oncogènes B‑raf, de l’âge 
et du sexe masculin. Cependant la plupart des études 
ont échoué à associer la grande partie de ces données 
avec la récurrence. 
L’objectif de l’etude a été d’évaluer la relation entre 
certaines constatations histopathologiques et mor‑
phologiques et la récurrence du cancer de la thyroïde 
ou la maladie persistante dans une cohorte de 393 pa‑
tients atteints de CDT.
Méthodes Nous avons rétrospectivement analysé 393 
patients ayant le diagnostic de CDT entre janvier 2000 
et décembre 2010.
Résultats L’analyse histopathologique a indiqué 
le carcinome papillaire chez 362 (%92,1) sujets et 
AbstRAct
Background. Differentiated thyroid cancer (DTC) is 
one of the most frequently observed neoplasms today. 
Recurrence of DTC has been previously reported to 
be dependent on tumor characteristics, the tumor size, 
the presence of lymph node metastasis, the presence of 
extra thyroid invasion, the presence of distant metas‑
tasis, oncogenes such as B‑RAF proto‑oncogene, ad‑
vanced age and male sex. However, many studies have 
failed to associate many of these data with relapse. 
The objective of the study was to evaluate the re‑
lationship between some histopathological and mor‑
phological findings with thyroid cancer relapse or per‑
sistent disease in a cohort of 393 DTC patients. 
Methods. We retrospectively analyzed 393 subjects 
with DTC, diagnosed in our institution between 
January 2000 and December 2010. 
Results. Histopathological analysis indicated papil‑
lary carcinoma in 362 (92.1%) subjects and follicular 
carcinoma in 31 (7.9%) subjects. Eighty‑two (20.9%) of 
the subjects relapsed or had persistent disease. Male 
subjects had a higher trend for relapse (RR 1.739 
%95 CI: 1.059‑2.856) p=0.029). 18.8% of female sub‑
jects relapsed or had persistent disease, whereas the 
relapse rate was 30.4% in male subjects. Every 1 cm 
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IntRoductIon
Differentiated thyroid cancer (DTC) is one of 
the most frequently observed neoplasms today, which 
is increasing in incidence secondary to increased us‑
age of imaging techniques. According to data ob‑
tained from the National Cancer Institute (NCI) 
Surveillance, Epidemiology and End Results program 
(SEER), the estimated number of new cases of thyroid 
cancer is 14.5 per 100,000 men and women per year1.
The prognosis of DTC has been proven to be 
excellent. However, several subjects undergo relapse. 
Recurrence of DTC has been previously reported to 
be dependent on tumor characteristics, the tumor 
size, the presence of lymph node metastasis, the pres‑
ence of extrathyroidal invasion, the presence of dis‑
tant metastasis, oncogenes such as B‑RAF proto‑on‑
cogene, advanced age and male sex2,3.
Age above 45 years has been linked to poor prog‑
nosis and recently a US study established that sub‑
jects above 60 years of age had even worse prognosis4. 
A meta‑analysis has detected that multifocality was 
also associated with poor cancer outcome5. Although 
some studies have not associated tumor diameter 
with relapse, many studies defend this relationship 
and a Korean study has shown that a tumor size >1.8 
cm, together with cervical lymph node metastasis 
and bilateral disease, were independent risk factors6. 
However, a recent cohort study involving 209 subjects 
detected that cervical lymph node metastasis was the 
only independent parameter linked to papillary thy‑
roid cancer relapse7. Male sex has been previously ar‑
gued to be linked to adverse prognosis8.
Our group has previously detected that stimu‑
lated thyroglobulin levels above 5.6 ng/mL were as‑
sociated with a 2.38‑fold risk of relapse in subjects 
with DTC3.
the objectIve of the study was to assess the as‑
sociation between some tumor characteristics with 
recurrence and persistent disease, in the same study 
population.
mAteRIAl And methods
Between 2000 and 2010, 436 subjects were 
diagnosed with DTC in our institution, Baskent 
University School of Medicine, Department of 
Endocrinology and Metabolism, Ankara, Turkey. 
Subjects having distant metastasis at diagnosis were 
excluded. Subjects with at least one year follow up 
after the whole‑body scan (WBS), performed 6‑12 
months after the initial treatment, were eligible for 
the study. We included 393 subjects who met these 
criteria in the study. 324 patients were female (82.4%) 
and 69 were male (17.6%)
le carcinome folliculaire chez 31 (7,9%) sujets. 82 
(20,9%) des sujets ont connu une récurrence ou une 
maladie persistante. Les patients masculins ont une 
tendance plus élevée de récurrence (RR 1,739%, 95 
CI: 1,059‑2,856) p=0,029). 18,8% des sujets féminins 
ont connu une récurrence ou une maladie persistante 
alors que le taux de récurrence est de 30,4% pour les 
sujets masculins. Chaque augmentation d’un cen‑
timètre de la taille de la tumeur augmente le risque 
de récurrence de 25% (RR 1,25, 95% CI: 1,11‑1,41, 
p<0,001). L’appartenance au sexe masculin, le diamè‑
tre du nodule et le diamètre de la tumeur ont été con‑
sidérés comme des paramètres indépendants pour la 
récurrence ou pour la maladie persistante (respective‑
ment p=0,002 ; p<0,0001, p<0,001).
Conclusion Nous démontrons ici que la tumeur et 
le sexe masculin sont les seuls paramètres affectant la 
récurrence ou la maladie persistante dans notre co‑
horte. Une raison possible des constats différents ob‑
tenus d’études diverses pourrait être la non‑standard‑
isation du protocole d’études et les taux de guérison 
chirurgicale.
Mots-clés: cancer différencié de la thyroïde, carci‑
nome papillaire, carcinome folliculaire, récurrence.
increase in tumor size increased the risk of relapse by 
25% (RR=1.25, 95% CI: 1.11‑1.41, p<0.001). Male sex, 
nodule diameter, and tumor diameter were detected 
to be independent parameters for relapse or persistent 
disease (p=0.002; p<0.0001, p<0.001 respectively). 
Conclusion. We demonstrated that tumor diameter 
and male sex were the only parameters affecting re‑
lapse or persistent disease in our cohort. A possible 
reason for different reports from different studies may 
be non‑standardization of study protocols and surgical 
cure rates.
Keywords: differentiated thyroid cancer, papillary 
carcinoma, follicular carcinoma, relapse.
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Total thyroidectomy was the initial treatment 
strategy in all subjects. Cervical ultrasonography (CUS) 
was performed by experienced endocrinologists, with a 
10 MHz probe (Logiq 5 Pro, GE medical systems, WI, 
USA). Prophylactic lymph node dissection was not per‑
formed. Lymph node dissection was only performed 
in subjects having radiologically evident pathological 
lymph nodes, determined by preoperative CUS.
According to the pathological analysis of the thy‑
roidectomy material, subjects were reported to have 
a papillary microcarcinoma, classical papillary thy‑
roid cancer (PTC), PTC follicular variant (FV), PTC 
Tall cell type, PTC insular type, classical follicular 
thyroid cancer (FTC) minimal invasive and classical 
FTC widely invasive.
Tumor size, multifocality, the presence of thy‑
roid capsule invasion, the presence of extrathyroidal 
organ invasion, the presence of vascular invasion, the 
presence of lymphatic invasion, the presence of tu‑
mor cells at surgical sites, the presence of invasion of 
the vascular fascia and presence of tracheal invasion 
were evaluated by pathologists in our institution. 
Subjects were staged according to the tumor node 
metastasis (TNM) of the American Joint Committee 
on Cancer (AJCC)9.
Subjects received radioactive iodine (RAI) abla‑
tion therapy, 6–8 weeks after surgery, following levo‑
thyroxine withdrawal. Subjects received 30–100 mCi 
of radioactive iodine (RAI), for those without capsu‑
lar invasion or cervical/distant metastasis. Subjects 
with an invasion of the thyroid capsule received 
100–150 mCi of RAI. Subjects with established cer‑
vical lymph node metastasis received 150–200 mCi of 
RAI. After RAI therapy, levothyroxine was initiated, 
to suppress TSH levels <0.1 ng/mL in the first year. 
Thyroglobulin (Tg) levels were defined to be positive 
if above 2 ng/mL in the stimulated period. Subjects 
were followed up with periodical Tg, thyroglobulin 
antibodies (Tg‑ab), TSH levels, and CUS evaluations. 
A diagnostic 131‑I whole body scan (WBS) was per‑
formed 9–12 months after the initial treatment.
Remission is defined as having a negative WBS 
performed 9–12 months after RAI therapy, having 
a negative stimulated Tg (<2 ng/mL), negative thy‑
roglobulin antibodies (Tg‑ab), and normal CUS. For 
those with positive Tg‑ab, remission is defined as hav‑
ing a negative WBS and normal CUS10. Subjects were 
also considered under remission in cases of low up‑
take in the thyroid bed with stimulated Tg <2 ng/mL.
In subjects having positive Tg levels (i.e. > 2 ng/
mL), recurrence was investigated by either WBS, CUS, 
computed tomography (CT), magnetic resonance 
imaging (MRI) and Positron Emission Tomography 
(PET). Suspicious cervical lymph nodes underwent a 
fine needle aspiration biopsy for cytological analysis.
Statistical Analysis
We used SPSS (Statistical Package for Social 
Sciences) version 15.0 for Windows. We used the 
Student’s T‑test and χ2 tests in addition to descriptive 
statistics when appropriate. Kaplan–Meier’s curves 
were used for disease‑free survival analysis. We used 
the logistic regression analysis for detecting independ‑
ent variables for relapse. A two‑sided p‑value <0.05 
was considered statistically significant.
Results
General properties of the study group
A total of 434 subjects were retrospectively ana‑
lyzed. Seven subjects had established metastases at 
diagnosis, 20 subjects did not receive RAI for rem‑
nant ablation, and in 16 subjects recombinant human 
TSH (rhTSH) was employed, thus they were exclud‑
ed, and the study was carried out with 393 subjects. 
Three hundred and ninety‑three subjects with DTC 
were eligible for this study and were retrospectively 
analyzed. Demographic properties of the study group 
are summarized in Table 1.
According to the ATA 2009 risk stratification 
system, 343 (87.2%) were low risk and 50 (12.8%) 
were an intermediate risk10.
The mean age of the study group was 43.84 ± 
13.54 years (range 16‑81 years). A total of 214 out 
of 393 were below 45 years of age (54.4%) and 179 
subjects were above 45 (45.6%). Three hundred and 
twenty‑four subjects were female (82.4%) and 69 
(17.6%) were male. The Female/Male ratio was 4.68. 
The mean maximum tumor size was 1.578 ± 1.33 cm 
(0.1‑9 cm). Thyroid capsule invasion was present in 
117/393 (29.8%) subjects.
Out of the 393 diagnosed subjects, 113 (28.8%) 
had a single thyroid nodule and the remaining 280 
(71.2%) were multinodular. 130 subjects had multifo‑
cal disease (33.1%). 43 subjects (10.9%) had metastatic 
cervical lymph nodes at presentation.
Out of the 393 subjects, 366 underwent bilateral 
near‑total thyroidectomy and 27 bilateral total thy‑
roidectomy and central lymph node dissection.
Histopathology revealed that 362 (92.1%) sub‑
jects had papillary thyroid cancer (PTC) and 31 had 
follicular thyroid cancer (FTC) (7.9%). The most 
common histological subtype was classical PTC in 
265 (67.4%) subjects, PTC follicular variant (FV) 
in 88 (22.4%) subjects, undifferentiated PTC in 9 
subjects (2.4%), micro‑invasive FTC in 23 subjects 
(5.9%) and invasive FTC in 8 (2%) subjects. Seventy 
subjects (17.8%) had histologically confirmed thy‑
roiditis.
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Association of risk factors with recurrence
Subjects were followed up for a mean of 64.4 
months after the primary surgical therapy (range 
14‑192 months). Eighty‑two subjects relapsed or had 
persistent disease (20.9%). The mean time to relapse 
was 16.7 months (4‑63 months).
Male subjects had a higher trend for relapse 
(RR 1.739 %95 CI: 1.059‑2.856) p=0.029). 18.8% of 
female subjects relapsed, whereas the relapse rate was 
30.4% for male subjects.
Multinodularity increased significantly the risk 
of relapse (RR 1.933 (95% CI 1.104‑3.384) p=0.021). 
Out of the 393 diagnosed subjects, 113 (28.8%) were 
uninodular and 280 (71.2%) were multinodular. 
Sixteen of the uninodular group relapsed (14.15%) 
whereas 66 of the multinodular group relapsed 
(23.5%). 263 subjects had unifocal disease, whereas 
130 were multifocal. The relapse rates were similar 
among subjects with unifocal and multifocal disease 
(33/130 (25.3%) vs 49/263 (18.6%)) p>0.05. 108 sub‑
jects of the multinodular group had the multifocal 
disease (38.6%).
The mean nodule diameter was 26.81 ± 18.29 
mm in 82 subjects who relapsed and 21.38±12.86 
mm in 311 subjects under remission. This compari‑
son was statistically significant (p=0.013). According 
to the tumor sizes measured histopathologically, 
the mean tumor size was 2.04±1.63cm in subjects 
who relapsed compared with a mean tumor size of 
1.45±1.21cm in subjects under remission. Every 1 cm 
increase in tumor size increased the risk of relapse by 
25% (RR=1.25, 95% CI: 1.11‑1.41, p<0.001).
The presence of thyroid capsule invasion in‑
creased the risk of relapse by 2‑fold (RR=2.011, 95% 
CI 1.3‑3.11, p=0.002). Thyroid capsule invasion was 
present in 117 subjects. Out of these, 36 relapsed 
(30.8%). Relapse occurred in 46/276 subjects without 
capsular invasion (16.6%).
The presence of cervical lymph node metastasis 
increased the risk of relapse by 2.76‑fold (RR=2.76, 
95% CI 1.63‑4.66, p<0.001). 43 subjects had meta‑
static cervical lymph nodes. 18 of these relapsed (41.8 
%). The disease‑free survival was 17.2±1.75 months in 
subjects with cervical lymph node metastasis, com‑
pared to 172.78±2.98 months in subjects without 
cervical lymph node metastasis. The comparison was 
statistically significant (p<0.001).
Age, the presence of histological thyroiditis and 
histological subtypes were similar among subjects 
who relapsed compared to those under remission.
These risk models were adjusted for sex, mul‑
ti‑nodularity, tumor diameter, the presence of cer‑
vical lymph node metastasis, and the presence of 
thyroid capsule invasion. Male sex, nodule diameter, 
and tumor diameter were detected to be independent 
parameters for relapse (p=0.002; p<0.0001, p<0.001 
respectively)
We used PET‑CT to evaluate the presence of dis‑
tant metastasis in 11 subjects with elevated Tg levels. 
We detected 7 metastases in this group (3 lung and 
4 lymph nodes).
Out of the 393 subjects, 366 underwent bilat‑
eral near‑total thyroidectomy and 27 bilateral total 
thyroidectomies together with central lymph node 
dissection. Subjects who underwent lymph node 
dissection had a shorter disease‑free survival, which 
was attributable to the presence of lymph node me‑
tastasis compared to subjects undergoing thyroidec‑
tomy (49.47± 8.49 months vs 60.75 ± 3.64 months, 
p<0.001).
Table 1. General characteristics of the study group
n (%)
Age
Age < 45 years 214 (54.4%)
Age> 45 years 179 (45.6%)
Sex
Male 69 (17.6%)
Female 324 (82.4%)
Nodularity
Uninodular 113 (28.8%)
Multinodular 280 (71.2%)
Focality
Unifocal 263 (66.9%)
Multifocal 130 (33.1%)
Thyroid Capsule invasion
Absent 276 (70.2%)
Present 117 (29.8%)
Histology
PTC
FTC
362 (92.1%)
31 (7.9%)
Thyroiditis
Present 70 (17.8%)
Absent 323 (82.2%)
TNM‑N
N1 43 (10.9%)
N0 350 (89.1%)
TNM‑T
T1‑T2
T3‑T4
Surgery
360 (92.3%)
33 (7.7%)
TT 366 (93.1%)
TT + LN dissection 27 (6.9%)
TNM: Tumor Node Metastasis; TT: Total Thyroidectomy; LN: 
Lymph Node; PTC: papillary thyroid cancer; FTC: Follicular 
thyroid cancer
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dIscussIon
In the present study, we demonstrated that tu‑
mor diameter and male sex were independent param‑
eters for DTC relapse.
The proportion of male subjects in the present 
study was similar to that previously reported, rang‑
ing between 2/1 and 4/111,12. Our study population 
consisted of 82.4% female subjects and 17.6% male 
subjects. We demonstrated that male subjects had a 
1.73‑fold increase in the risk of relapse or persistent 
disease compared to female subjects. Some previous 
studies have reported similar findings, whereas many 
have failed to demonstrate such a relationship. A 
study by Sin‑Ming Chow et al included 203 subjects 
with PTC in their study, which consisted of 86.7% 
female subjects and 13.3% male subjects. They estab‑
lished no relationship between gender and relapse13. 
Another study, which involved 1516 subjects with 
PTC, revealed that lung metastasis was more frequent 
in male subjects14. Like this study, Clark et al estab‑
lished that distant metastasis was more frequently ob‑
served in male subjects15. A study published in 2012, 
involving 435 subjects with DTC, demonstrated that 
both relapse and mortality were higher in male sub‑
jects8.
In the present study, tumor diameter was as‑
sociated with relapse or persistent disease. Every 1 
cm increase in tumor size increased the risk of re‑
lapse by 25% (RR=1.25, 95% CI: 1.11‑1.41, p <0.001). 
Although some studies have not associated tumor 
diameter with relapse, many studies defend this rela‑
tionship and a Korean study has shown that a tumor 
size >1.8 cm, together with cervical lymph node me‑
tastasis and bilateral disease, were independent risk 
factors6.
There was no relationship between multifocality, 
the presence of histologically confirmed thyroiditis, 
age, histological subtype, and relapse. Multifocality 
has previously been argued as an adverse prognostic 
factor. A study by Pellegrini et al established that bi‑
lateral disease in subjects with PTC was a risk factor 
for relapse16. Baudin et al established that the number 
of histological foci significantly increased the risk of 
relapse17. Similar to our results, Ito Y et al established 
no such relationship18.
Souza et al determined in their study that the 
presence of autoimmune thyroiditis had a favorable 
effect on PTC prognosis19, whereas similar to our 
study Huang et al determined that presence of thy‑
roiditis had no effect on PTC and FTC prognosis20.
We established that the presence of capsule in‑
vasion increased the risk of relapse by 2.01‑fold. A 
study by Furlan et al established that capsule invasion 
was not associated with prognosis in a cohort of 350 
PTC21. Haq et al also observed similar findings22.
An interesting finding of our study was that mul‑
tinodularity increased the risk of relapse by 1.93‑fold. 
Kappur et al established that subjects with a solitary 
tumor with a multinodular thyroid gland had a high‑
er rate of metastasis compared to those with a solitary 
nodule23. However, in the multivariate analysis, this 
factor was not defined to be an independent risk fac‑
tor.
conclusIons
Many factors have been incriminated to increase 
the risk of thyroid cancer relapse and conflicting re‑
sults have been obtained. We demonstrated in our 
study that tumor diameter and male sex were the only 
parameters affecting relapse or persistent disease in 
our cohort. A possible reason for different reports 
from different studies may be non‑standardization of 
study protocols and surgical cure rates.
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